# A Phase III Randomized, Double-blind, Parallel-group Study to Evaluate the Efficacy and Safety of Acarmet (Metformin HCl 500 mg Plus Acarbose 50 mg Tablets) Versus Acarbose Alone in Subjects With Type 2 Diabetes Mellitus

> **NCT01245166** · PHASE3 · UNKNOWN · sponsor: **Lotus Pharmaceutical** · enrollment: 220 (estimated)

## Conditions studied

- The Objectives of the Study is to Evaluate the Efficacy and Safety of Acarmet (Metformin HCl 500 mg
- Plus Acarbose 50 mg Tablets) Thrice Daily Versus Acarbose 50 mg Thrice Daily Over 16 Weeks in
- Subjects With Type 2 Diabetes Mellitus.

## Interventions

- **DRUG:** Acarbose
- **DRUG:** Metformin/Acarbose

## Key facts

- **NCT ID:** NCT01245166
- **Lead sponsor:** Lotus Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2010-11
- **Primary completion:** 2011-06
- **Final completion:** 2011-12
- **Target enrollment:** 220 (ESTIMATED)
- **Last updated:** 2010-11-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01245166

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01245166, "A Phase III Randomized, Double-blind, Parallel-group Study to Evaluate the Efficacy and Safety of Acarmet (Metformin HCl 500 mg Plus Acarbose 50 mg Tablets) Versus Acarbose Alone in Subjects With Type 2 Diabetes Mellitus". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01245166. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*